Mega menu

Home
Product regulation
Product regulation

Understand your obligations and access industry Guidance and other information about the products we regulate.
Safety and shortages
Safety and shortages

Access information about product recalls, shortages and other alerts, and learn how we manage safety.
Resources and guidance
Resources and guidance

Get information to help you understand our work, regulations and industry obligations.
Business services
Business services

Access our systems to submit applications, manage forms, make payments and communicate securely.

Otsuka Australia Pharmaceutical Pty Ltd

Regulatory activities for this sponsor.

- LinkedIn
- (Twitter)
- Facebook
- Email

Loading...

Type

ARTG (15)
Cancellation by sponsor (7)
Australian Public Assessment Report (AusPAR) (3)
Prescription medicine registration (2)
Designation or determination (1)
Prescription medicine decision summary (1)
Prescription medicine evaluation (1)

Date

2026 (4)
2025 (2)
2021 (3)
2020 (1)
2019 (1)
2018 (1)
2017 (5)
2016 (4)
2012 (2)
2008 (1)
2003 (6)

Search

Sponsor content

30 result(s) found, displaying 11 to 20

JINARC tolvaptan 30 mg tablet blister pack (272786)

24 March 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg tablet blister pack.
JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack (272788)

24 March 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack.
JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack (272787)

24 March 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack.
JINARC tolvaptan 15 mg tablet blister pack (272785)

24 March 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg tablet blister pack.
JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack (272789)

24 March 2017

ARTG

Australian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 90 mg tablet blister composite pack.
ABILIFY INJECTION aripiprazole 9.75 mg solution for injection vial Cancelled under Section 30(1)(c) of the Act

23 July 2019

Cancellation by sponsor

Requested by Otsuka Australia Pharmaceutical Pty Ltd
AusPAR: Tolvaptan

22 February 2018

Australian Public Assessment Report (AusPAR)

Australian Public Assessment Report for Tolvaptan
ABILIFY ODT aripiprazole 10mg orally disintegrating tablet blister pack Cancelled under s30(1)(c)

22 December 2016

Cancellation by sponsor

Requested by Otsuka Australia Pharmaceutical Pty Ltd
ABILIFY ODT aripiprazole 15mg orally disintegrating tablet blister pack Cancelled under s30(1)(c)

22 December 2016

Cancellation by sponsor

Requested by Otsuka Australia Pharmaceutical Pty Ltd
ABILIFY ODT aripiprazole 20mg orally disintegrating tablet blister pack Cancelled under s30(1)(c)

22 December 2016

Cancellation by sponsor

Requested by Otsuka Australia Pharmaceutical Pty Ltd

Pages

First page
Previous page
Page 1
Current page 2
Page 3
Next page
Last page

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information
Acronyms and glossary terms

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control
State and territory contacts

Connect with us

Email subscriptions
Contact us
Facebook
(formerly Twitter)
Youtube
Instagram
LinkedIn

Help us improve

We are always looking for ways to improve our website.

Provide feedback

The Department of Health, Disability and Ageing acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.